| Xu, Ruihua |
JUPITER-02, NCT03581786: The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer |
|
|
| Active, not recruiting | 3 | 289 | RoW | TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy, Placebos | Shanghai Junshi Bioscience Co., Ltd. | Recurrent or Metastatic NPC | 05/20 | 10/22 | | |
|
|
|
|
| Completed | 3 | 514 | RoW | Toripalimab, JS001, TAB001 | Shanghai Junshi Bioscience Co., Ltd. | Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy | 03/21 | 09/23 | | |
|
|
|
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
FRUTIGA, NCT03223376: A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer |
|
|
| Active, not recruiting | 3 | 703 | RoW | fruquintinib +paclitaxel, HMPL-013+paclitaxel, fruquintinib placebo + paclitaxel, HMPL-013 placebo+paclitaxel | Hutchison Medipharma Limited, Sun Yat-sen University | Advanced Gastric Cancer | 09/22 | 11/22 | | |
|
|
|
|
CLASSIC, NCT04262635: Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 3 | 80 | RoW | Cetuximab, Capecitabine, Cetuximab | Sun Yat-sen University | Colorectal Cancer | 12/22 | 08/24 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
NCT06296706: A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer |
|
|
| Not yet recruiting | 3 | 630 | NA | Docetaxel for injection (Albumin-bound), HB1801, Taxotere (docetaxel), Taxotere | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Gastric Cancer | 06/26 | 06/27 | | |
NCT06022861: A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 510 | RoW | LY01015, Fluorouracil, Cisplatin, Opdivo® | Shandong Boan Biotechnology Co., Ltd | Esophageal Squamous Cell Carcinoma | 06/25 | 12/26 | | |
NCT03671252: Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation |
|
|
| Recruiting | 3 | 776 | RoW | FOLFOXIRI, XELOX, Chemoradiotherapy, TME operation, efficacy evaluation | Sun Yat-sen University | Rectal Cancer | 09/25 | 09/28 | | |
NCT05768503: Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC |
|
|
| Recruiting | 3 | 176 | RoW | Experimental drug, CAP, Control Rx, FOLFIRI+BEV | Sun Yat-sen University | Metastatic Microsatellite-stable Colorectal Cancer | 01/26 | 01/27 | | |
NOTABLE-307, NCT05978050: Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 354 | NA | nimotuzumab plus paclitaxel, Combined with chemotherapy, placebo plus paclitaxel, chemotherapy alone | Biotech Pharmaceutical Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 03/26 | 03/26 | | |
NCT05918094: Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 3 | 540 | RoW | Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab | Sun Yat-sen University | Gastric Cancer | 12/26 | 12/28 | | |
CIBI310L301, NCT05890742: A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer |
|
|
| Recruiting | 3 | 360 | RoW | Sintilimab, IBI310&Sintilimab, Radical surgery | Innovent Biologics (Suzhou) Co. Ltd. | MSI-H | 04/28 | 07/28 | | |
NCT04856787: A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC |
|
|
| Recruiting | 2/3 | 439 | RoW | SHR-1701、 BP102 、XELOX, placebo、 BP102、 XELOX | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Metastatic Colorectal Cancer (mCRC) | 11/22 | 11/24 | | |
ASTRUM-015, NCT04547166: A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) |
|
|
| Recruiting | 2/3 | 568 | Japan, RoW | HLX10, serplulimab, HLX04、, Bevacizumab | Shanghai Henlius Biotech | Metastatic Colorectal Cancer | 09/25 | 12/26 | | |
NCT05945901: A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer |
|
|
| Recruiting | 2/3 | 606 | RoW | HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab, HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab | Jiangsu HengRui Medicine Co., Ltd. | Colorectal Cancer | 12/25 | 12/26 | | |
NCT04724239: Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma |
|
|
| Active, not recruiting | 2 | 48 | RoW | Sintilimab, Chidamide, IBI305, Bevacizumab | Sun Yat-sen University | Advanced Microsatellite Stable Colorectal Cancer, Metastatic Microsatellite-stable Colorectal Cancer | 07/22 | 12/23 | | |
NCT04603040: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers |
|
|
| Recruiting | 2 | 100 | RoW | Toripalimab, Tuoyi | Shanghai Junshi Bioscience Co., Ltd. | Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy | 12/22 | 03/23 | | |
NCT05705635: A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer |
|
|
| Recruiting | 2 | 100 | RoW | Docetaxel for injection (Albumin-bound), Taxotere | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Gastric Adenocarcinoma, Adenocarcinoma of Gastroesophageal Junction | 05/23 | 12/24 | | |
NCT05117658: Study of HA121-28 in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 83 | RoW | HA121-28 tablet | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NSCLC | 10/23 | 10/23 | | |
NCT05163483: Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer |
|
|
| Recruiting | 2 | 87 | RoW | Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, Tucidinostat (chidamide) JS001 | Ruihua Xu | Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma | 12/23 | 12/25 | | |
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 238 | RoW | MRG003, Capecitabine tablets, Docetaxel injection | Shanghai Miracogen Inc. | Recurrent or Metastatic Nasopharyngeal Carcinoma | 10/24 | 02/25 | | |
NCT05962502: Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy |
|
|
| Recruiting | 2 | 54 | RoW | Cetuximab and irinotecan, ERBITUX | Sun Yat-sen University | Metastatic Colorectal Cancer | 03/25 | 12/26 | | |
| Recruiting | 2 | 114 | RoW | Paclitaxel, Cisplatin, Taxol, tislelizumab, Radiotherapy, intensity-modulated radiotherapy | Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Zhongshan People's Hospital, Guangdong, China, Jieyang People's Hospital | Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma | 07/25 | 07/26 | | |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
NCT02915432: The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC |
|
|
| Active, not recruiting | 1/2 | 401 | RoW | 3 mg/kg anti-PD-1 mAb JS001 Q2W, toripalimab, TAB001, 360 mg anti-PD-1 mAb JS001 Q3W, 240mg anti-PD-1 mAb JS001 Q3W | Shanghai Junshi Bioscience Co., Ltd. | Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma | 02/20 | 04/22 | | |
NCT04856774: Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors |
|
|
| Completed | 1/2 | 81 | RoW | SHR-1701；BP102 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 03/24 | 03/24 | | |
NCT04685226: A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 310 | RoW | ICP-723 | Beijing InnoCare Pharma Tech Co., Ltd. | Solid Tumors | 06/25 | 02/28 | | |
NCT04284488: Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors |
|
|
| Recruiting | 1/2 | 104 | RoW | APG-1387 for Injection, Toripalimab, JS001 | Ascentage Pharma Group Inc. | Advanced Solid Tumor | 04/24 | 04/24 | | |
NCT06376136: A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors |
|
|
| Recruiting | 1/2 | 108 | RoW | BAT8010 for Injection, BAT1006 for Injection | Bio-Thera Solutions | Advanced Solid Tumors | 12/24 | 12/26 | | |
NCT05745623: A Phase 2 Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors |
|
|
| Recruiting | 1/2 | 55 | RoW | ICP-723 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion | 06/24 | 12/26 | | |
NCT05688605: A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 18 | RoW | MRG003+HX008 | Shanghai Miracogen Inc. | Advanced Solid Tumors | 05/25 | 07/25 | | |
| Active, not recruiting | 1/2 | 49 | Europe, Japan, US, RoW | TAK-981, Pembrolizumab | Takeda, Takeda Development Center Americas, Inc. | Advanced or Metastatic Solid Tumors | 11/25 | 11/25 | | |
NCT05877651: MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy. |
|
|
| Completed | 1 | 22 | RoW | MASCT-I injection | SYZ Cell Therapy Co.. | Solid Tumors | 10/21 | 10/21 | | |
NCT05015309: A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor |
|
|
| Not yet recruiting | 1 | 40 | RoW | SH3765 tablet | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Advanced Malignant Tumor | 03/23 | 09/24 | | |
NCT05380882: Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers |
|
|
| Recruiting | 1 | 60 | RoW | TQB2930 injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Cancers | 04/23 | 12/23 | | |
NCT03544905: Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33 |
|
|
| Recruiting | 1 | 100 | RoW | CYH33 for tablet | Haihe Biopharma Co., Ltd. | Advanced Solid Tumors | 06/23 | 03/24 | | |
MASCT-I, NCT03034304: A Phase I Clinical Study for Evaluating the Safety and Efficacy of in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 193 | RoW | MASCT-I, Ifosfamide, PD1 antibody, Adriamycin, Gemcitabine, Cisplatin, Carboplatin | SYZ Cell Therapy Co.. | Advanced Solid Tumors | 07/23 | 07/23 | | |
NCT05061628: The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor |
|
|
| Recruiting | 1 | 176 | RoW | JS006 as Monotherapy, JS006 in combination with Toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Advanced Tumors | 08/23 | 09/24 | | |
NCT04877717: A Study of SHR-A1904 in Patients With Advanced Solid Cancer |
|
|
| Recruiting | 1 | 94 | RoW | SHR-A1904 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Cancer | 10/23 | 01/24 | | |
NCT06166472: A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor |
|
|
| Not yet recruiting | 1 | 72 | RoW | AK132 | Akeso | Advanced Malignant Solid Tumor | 04/26 | 07/26 | | |
NCT05751486: A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 1 | 24 | RoW | Toripalimab injection(subcutaneous)/JS001sc, Toripalimab /JS001 | Shanghai Junshi Bioscience Co., Ltd. | Advanced Nasopharyngeal Carcinoma | 12/23 | 12/25 | | |
| Recruiting | 1 | 270 | RoW | NBL-028 | NovaRock Biotherapeutics, Ltd | Advanced Solid Tumor | 01/27 | 01/27 | | |
NCT05735496: Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers |
|
|
| Not yet recruiting | 1 | 71 | RoW | TQB2102 injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Cancer | 04/24 | 10/24 | | |
NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
| Recruiting | 1 | 924 | RoW | SHR-A1904; Adebrelimab, SHR-A1904; CAPOX; Adebrelimab | Shanghai Hengrui Pharmaceutical Co., Ltd. | Cldn18.2-positive Advanced Solid Tumor | 12/27 | 12/28 | | |
NCT05385692: A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-M02D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Digestive Tract Tumors, Solid Tumor | 06/24 | 06/24 | | |
NCT05690581: Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies |
|
|
| Recruiting | 1 | 146 | RoW | CM369 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumors and Hematologic Malignancies | 06/24 | 04/25 | | |
NCT05867303: A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 48 | RoW | RC198 Injection | RemeGen Co., Ltd. | Melanoma, Urothelial Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma | 06/24 | 09/24 | | |
NCT05502393: A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 118 | RoW | JS107, Toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Advanced Solid Tumors | 07/24 | 12/24 | | |
| Recruiting | 1 | 100 | RoW | HQP1351 | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult | 12/24 | 12/26 | | |
NCT05781386: A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors |
|
|
| Recruiting | 1 | 255 | RoW | SIM1811-03 or in combination with Sintilimab injectiont | Jiangsu Simcere Biologics Co., Ltd | Advanced Solid Tumor, Cutaneous T Cell Lymphoma | 06/25 | 12/25 | | |
NCT05979155: A Study of NWY001 in Subjects With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 196 | RoW | NWY001 | Chipscreen Biosciences, Ltd. | Advanced Solid Tumor | 01/26 | 05/28 | | |
NCT06094556: An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 240 | RoW | SHR-1826 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 06/27 | 07/27 | | |
| Completed | N/A | 210 | RoW | Breathing test | Mian XI | Esophageal Squamous Cell Carcinoma | 10/23 | 11/23 | | |
| Xu, Rui-hua |
NCT03837808: Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 384 | RoW | Nimotuzumab, Cisplatin | Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong Provincial People's Hospital, First Affiliated Hospital, Sun Yat-Sen University | Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm | 02/24 | 02/24 | | |
NCT03840421: GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 3 | 468 | RoW | gemcitabine and cisplatin, gemcitabine and cisplatin (GP), cisplatin and fluorouracil, cisplatin and fluorouracil (PF), IMRT, cisplatin, cisplatin（DDP） | Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong Provincial People's Hospital, First Affiliated Hospital, Sun Yat-Sen University | Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm | 08/26 | 12/28 | | |
NCT03671252: Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation |
|
|
| Recruiting | 3 | 776 | RoW | FOLFOXIRI, XELOX, Chemoradiotherapy, TME operation, efficacy evaluation | Sun Yat-sen University | Rectal Cancer | 09/25 | 09/28 | | |
NCT05737563: PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC |
|
|
| Recruiting | 3 | 380 | RoW | PD-1 Inhibitors, Irinotecan, Capecitabine tablets | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd., Jiangsu HengRui Medicine Co., Ltd. | Esophageal Squamous Cell Carcinoma Abdominal Stage 0 | 02/26 | 02/26 | | |
NCT04250948: Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer |
|
|
| Active, not recruiting | 2 | 108 | RoW | JS001, PD-1 antibody, Oxaliplatin, S1, Capecitabine, XELODA | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd. | Gastric Cancer, Locally Advanced Solid Tumor | 06/22 | 10/24 | | |
NCT05163483: Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer |
|
|
| Recruiting | 2 | 87 | RoW | Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, Tucidinostat (chidamide) JS001 | Ruihua Xu | Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma | 12/23 | 12/25 | | |
NCT03810339: Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors |
|
|
| Recruiting | 2 | 35 | RoW | Toripalimab | Sun Yat-sen University | Solid Tumor, Advanced Cancer | 01/24 | 01/24 | | |
NCT06396637: PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC |
|
|
| Recruiting | 2 | 20 | RoW | Sapropterin Dihydrochloride, PD-1 Antibody | Sun Yat-sen University, Innovent Biologics (Suzhou) Co. Ltd. | Pancreatic Adenocarcinoma Metastatic | 04/25 | 04/25 | | |
NCT05173246: JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma |
|
|
| Recruiting | 2 | 43 | RoW | JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection, nab-paclitaxel, Paclitaxel for injection (Albumin Bound), Cisplatin, Cisplatin for injection, Carboplatin, Carboplatin for injection | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd., CSPC Ouyi Pharmaceutical Co., Ltd. | Esophageal Small Cell Carcinoma | 11/24 | 11/25 | | |
NCT05576961: Safety and Efficacy of RX-af01 Combined With PD-1 Antibody |
|
|
| Recruiting | 1/2 | 60 | RoW | RX-af01, Toripalimab, Mixed bacteria, High dose RX-af01 | Sun Yat-sen University | Solid Tumor, Immune Checkpoint Inhibitor, Intestinal Flora | 12/24 | 12/24 | | |
| Wang, Feng |
NCT05049681: Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell |
|
|
| Not yet recruiting | 3 | 234 | NA | Camrelizumab, SHR-1210, Apatinib | Feng Wang | Esophageal Cancer | 12/22 | 06/23 | | |
NCT06301854: Long-term Safety of TPN171H Tablet in Erectile Dysfunction. |
|
|
| Recruiting | 3 | 400 | RoW | TPN171H, Simmerafil | Vigonvita Life Sciences | Erectile Dysfunction | 04/25 | 04/25 | | |
NCT05768503: Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC |
|
|
| Recruiting | 3 | 176 | RoW | Experimental drug, CAP, Control Rx, FOLFIRI+BEV | Sun Yat-sen University | Metastatic Microsatellite-stable Colorectal Cancer | 01/26 | 01/27 | | |
NCT05737563: PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC |
|
|
| Recruiting | 3 | 380 | RoW | PD-1 Inhibitors, Irinotecan, Capecitabine tablets | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd., Jiangsu HengRui Medicine Co., Ltd. | Esophageal Squamous Cell Carcinoma Abdominal Stage 0 | 02/26 | 02/26 | | |
NCT05918094: Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 3 | 540 | RoW | Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab | Sun Yat-sen University | Gastric Cancer | 12/26 | 12/28 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
CAP 02, NCT03736863: Study of Anti-PD-1/PD-L1 Antibody Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell |
|
|
| Recruiting | 2 | 125 | RoW | Apatinib+ SHR-1210（Camrelizumab）, Apatinib+ SHR-1316（Adebrelimab） | The First Affiliated Hospital of Zhengzhou University | Esophageal Cancer | 06/21 | 12/24 | | |
NCT03387904: Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 120 | RoW | Anlotinib Plus Irinotecan, Irinotecan | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 12/21 | 12/22 | | |
NCT04514835: A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC |
|
|
| Not yet recruiting | 2 | 44 | RoW | Cisplatin+Capecitabine+Sintilimab | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 01/22 | 01/23 | | |
NCT04654403: Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer |
|
|
| Not yet recruiting | 2 | 337 | RoW | Camrelizumab, SHR-1210 | The First Affiliated Hospital of Zhengzhou University | Esophageal Cancer | 05/22 | 12/22 | | |
NCT04888403: Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 45 | RoW | Toripalimab+Nedaplatin+Albumin Paclitaxel | The First Affiliated Hospital of Zhengzhou University | Locally Advanced Esophageal Squamous Cell Carcinoma | 07/22 | 07/22 | | |
NCT04157140: Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC |
|
|
| Recruiting | 2 | 48 | RoW | Anlotinib, TACE+RFA | Jinglong Chen | Hepatocellular Carcinoma | 09/22 | 03/23 | | |
NCT04533490: A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 42 | NA | SHR-1210 | The First Affiliated Hospital of Zhengzhou University | Resectable Esophageal Squamous Cell Carcinoma | 10/22 | 10/23 | | |
NCT03766178: Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 45 | RoW | Nimotuzumab + SHR-1210 | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 12/22 | 09/23 | | |
NCT04984018: Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade |
|
|
| Not yet recruiting | 2 | 73 | NA | chidamide + camrelizumab | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 12/22 | 12/23 | | |
NCT05241899: A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer |
|
|
| Not yet recruiting | 2 | 56 | RoW | Fruquintinib + RC48 | The First Affiliated Hospital of Zhengzhou University | Gastric Cancer | 05/23 | 05/25 | | |
EASOAIPPGL, NCT05133349: A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial |
|
|
| Recruiting | 2 | 20 | RoW | Anlotinib | Nanjing First Hospital, Nanjing Medical University | Advanced or Metastatic Paraganglioma/ Pheochromocytoma | 09/23 | 12/23 | | |
SHR-1210-02, NCT03917966: The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC |
|
|
| Recruiting | 2 | 80 | RoW | SHR-1210+docetaxel+nedaplatin, SHR-1210+Apatinib | The First Affiliated Hospital of Zhengzhou University, Jiangsu HengRui Medicine Co., Ltd. | Locally Advanced Esophageal Squamous Cell Carcinoma | 10/23 | 10/24 | | |
NCT05163483: Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer |
|
|
| Recruiting | 2 | 87 | RoW | Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, Tucidinostat (chidamide) JS001 | Ruihua Xu | Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma | 12/23 | 12/25 | | |
NCT03810339: Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors |
|
|
| Recruiting | 2 | 35 | RoW | Toripalimab | Sun Yat-sen University | Solid Tumor, Advanced Cancer | 01/24 | 01/24 | | |
NCT05738434: Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC |
|
|
| Recruiting | 2 | 188 | RoW | Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib, Camrelizumab+Chemotherapy→Camrelizumab | The First Affiliated Hospital of Zhengzhou University | Esophageal Cancer by AJCC V8 Stage | 07/24 | 11/26 | | |
NCT06439550: Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC |
|
|
| Not yet recruiting | 2 | 42 | NA | Serplulimab, Trastuzumab, Oxaliplatin + Tegafur, SOX | The First Affiliated Hospital of Zhengzhou University | HER2-positive Gastric Cancer | 12/26 | 12/26 | | |
NCT05896787: Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) |
|
|
| Not yet recruiting | 2 | 45 | RoW | AK104, nab-paclitaxel, carboplatin, Candonilimab，Preoperative Chemotherapy | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 08/24 | 08/26 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
NCT04819971: Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC |
|
|
| Recruiting | 2 | 67 | RoW | Tirelizumab, Trastuzumab, Docetaxel, S1, Oxaliplatin | The First Affiliated Hospital of Zhengzhou University | Stomach Cancer | 12/25 | 12/25 | | |
NCT05024812: Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 1/2 | 64 | RoW | fruquintinib＋toripalimab + SOX | The First Affiliated Hospital of Zhengzhou University | Metastatic Gastric Cancer | 08/23 | 02/25 | | |
NCT05330065: A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion |
|
|
| Not yet recruiting | 1/2 | 55 | NA | bevacizumab and camrelizumab | The First Affiliated Hospital of Zhengzhou University | Malignant Pleural Effusion | 08/23 | 08/24 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT05441046: Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 120 | RoW | Genakumab, Tislelizumab | GeneScience Pharmaceuticals Co., Ltd. | Malignant Solid Tumors | 06/24 | 03/25 | | |
NCT05043675: Clinical Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients |
|
|
| Recruiting | 1 | 6 | RoW | [18F]APN-1607, [18F]PBB3 | Nanjing First Hospital, Nanjing Medical University | Alzheimer Disease | 09/24 | 09/24 | | |
NCT06050239: Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer |
|
|
| Recruiting | 1 | 10 | RoW | 177Lu-PSMA-0057 | Nanjing First Hospital, Nanjing Medical University | Metastatic Prostate Cancer | 03/25 | 03/25 | | |
NCT05197673: Identifying Risks of COVID-19 Outbreaks in Work Settings and the Implications for Control Measures |
|
|
| Completed | N/A | 310 | RoW | Theory of planned behaviours (TPB) based intervention | Chinese University of Hong Kong | Intention to Get SARS-CoV-2 Vaccination, Intention to Get SARS-CoV-2 Antibody Test | 04/23 | 05/23 | | |
NCT05048810: Clinical Application of 68Ga-DOTA-NT-20.3 in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma |
|
|
| Completed | N/A | 6 | RoW | 68Ga-DOTA-NT-20.3 | Nanjing First Hospital, Nanjing Medical University | Pancreatic Ductal Adenocarcinoma | 03/23 | 03/23 | | |
| Recruiting | N/A | 349 | RoW | CAPEOX adjuvant therapy, deferred CAPEOX adjuvant therapy, mFOLFOXIRI intensive adjuvant therapy | Sun Yat-sen University, Guangzhou Burning Rock Dx Co., Ltd. | Colorectal Cancer | 07/28 | 07/28 | | |
NCT06054789: Clinical Study on 68Ga-PSMA-33 for PET/CT Imaging of Prostate Cancer |
|
|
| Recruiting | N/A | 8 | RoW | 68Ga-PSMA-33, 68Ga-PSMA-617 | Nanjing First Hospital, Nanjing Medical University | Prostate Cancer | 10/23 | 10/24 | | |
